X4 PHARMACEUTICALS INC (XFOR) Stock Price & Overview
NASDAQ:XFOR • US98420X2027
Current stock price
The current stock price of XFOR is 4.21 USD. Today XFOR is down by -3.22%. In the past month the price increased by 24.29%. In the past year, price decreased by -32.43%.
XFOR Key Statistics
- Market Cap
- 368.122M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -4.34
- Dividend Yield
- N/A
XFOR Stock Performance
XFOR Stock Chart
XFOR Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to XFOR. When comparing the yearly performance of all stocks, XFOR is a bad performer in the overall market: 79.89% of all stocks are doing better.
XFOR Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to XFOR. While XFOR seems to be doing ok healthwise, there are quite some concerns on its profitability.
XFOR Earnings
On March 17, 2026 XFOR reported an EPS of -0.22 and a revenue of 2.57M. The company beat EPS expectations (37.93% surprise) and beat revenue expectations (45.25% surprise).
XFOR Forecast & Estimates
9 analysts have analysed XFOR and the average price target is 11.9 USD. This implies a price increase of 182.66% is expected in the next year compared to the current price of 4.21.
For the next year, analysts expect an EPS growth of 74.46% and a revenue growth -70.41% for XFOR
XFOR Groups
Sector & Classification
XFOR Financial Highlights
Over the last trailing twelve months XFOR reported a non-GAAP Earnings per Share(EPS) of -4.34. The EPS increased by 79.62% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -27.27% | ||
| ROE | -42.51% | ||
| Debt/Equity | 0.41 |
XFOR Ownership
XFOR Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.04 | 380.121B | ||
| AMGN | AMGEN INC | 15.24 | 190.443B | ||
| GILD | GILEAD SCIENCES INC | 15.75 | 174.171B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.58 | 113.617B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.13 | 82.171B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.69 | 43.596B | ||
| INSM | INSMED INC | N/A | 35.536B | ||
| NTRA | NATERA INC | N/A | 28.801B | ||
| BIIB | BIOGEN INC | 11.01 | 26.972B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.92 | 24.995B | ||
| MRNA | MODERNA INC | N/A | 19.759B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.548B | ||
| INCY | INCYTE CORP | 12.15 | 18.767B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find more growth stocks the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About XFOR
Company Profile
X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. The company is headquartered in Boston, Massachusetts. The company went IPO on 2017-11-16. The firm is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. The company has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). The company has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
Company Info
IPO: 2017-11-16
X4 PHARMACEUTICALS INC
61 North Beacon Street, 4th Floor
Boston MASSACHUSETTS 02134 US
CEO: Paula Ragan
Employees: 143
Phone: 18575298300
X4 PHARMACEUTICALS INC / XFOR FAQ
What does X4 PHARMACEUTICALS INC do?
X4 Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and discovery of novel therapeutics for the treatment of rare diseases and those with limited treatment options. The company is headquartered in Boston, Massachusetts. The company went IPO on 2017-11-16. The firm is focused on discovering and developing novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. Its lead clinical candidate is mavorixafor, a small-molecule selective antagonist of chemokine receptor CXCR4. The company has developed a small-molecule, oral antagonists of the chemokine receptor C-X-C receptor type 4 (CXCR4). The company has two pre-clinical candidates: X4P-003, a second-generation CXCR4 antagonist designed to have enhanced properties relative to mavorixafor, potentially enabling opportunities in CXCR4-dependent disorders and primary immunodeficiencies, and X4P-002, a CXCR4 antagonist with a distribution profile and a demonstrated ability to cross the blood-brain barrier.
What is the current price of XFOR stock?
The current stock price of XFOR is 4.21 USD. The price decreased by -3.22% in the last trading session.
Does X4 PHARMACEUTICALS INC pay dividends?
XFOR does not pay a dividend.
What is the ChartMill rating of X4 PHARMACEUTICALS INC stock?
XFOR has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of X4 PHARMACEUTICALS INC (XFOR) based on its PE ratio?
X4 PHARMACEUTICALS INC (XFOR) does not have a PE ratio as the earnings reported over the last twelve months were negative (-4.34).
Can you provide the number of employees for X4 PHARMACEUTICALS INC?
X4 PHARMACEUTICALS INC (XFOR) currently has 143 employees.
What is X4 PHARMACEUTICALS INC worth?
X4 PHARMACEUTICALS INC (XFOR) has a market capitalization of 368.12M USD. This makes XFOR a Small Cap stock.